Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma

Glen Reid, M Pel, Michaela Kirschner, Yuen Yee Cheng, N Mugridge, J Weiss, M Williams, C Wright, James Edelman, Michael Vallely, Brian McCaughan, Sonja Klebe, H Brahmbhatt, J MacDiarmid, Nico van Zandwijk

    Research output: Contribution to journalArticle

    108 Citations (Scopus)

    Abstract

    Background: Malignant pleural mesothelioma (MPM) is recalcitrant to treatment and new approaches to therapy are needed. Reduced expression of miR-15/16 in a range of cancer types has suggested a tumour suppressor function for these microRNAs, and re-expression has been shown to inhibit tumour cell proliferation. The miR-15/16 status in MPM is largely unknown. Materials and methods: MicroRNA expression was analysed by TaqMan-based RT-qPCR in MPM tumour specimens and cell lines. MicroRNA expression was restored in vitro using microRNA mimics, and effects on proliferation, drug sensitivity and target gene expression were assessed. Xenograft-bearing mice were treated with miR-16 mimic packaged in minicells targeted with epidermal growth factor receptor (EGFR)-specific antibodies. Results: Expression of the miR-15 family was consistently downregulated in MPM tumour specimens and cell lines. A decrease of 4-to 22-fold was found when tumour specimens were compared with normal pleura. When MPM cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2-to 10-fold. Using synthetic mimics to restore miR-15/16 expression led to growth inhibition in MPM cell lines but not in MeT-5A cells. Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. In xenograft-bearing nude mice, intravenous administration of miR-16 mimics packaged in minicells led to consistent and dose-dependent inhibition of MPM tumour growth. Conclusions: The miR-15/16 family is downregulated and has tumour suppressor function in MPM. Restoring miR-16 expression represents a novel therapeutic approach for MPM.

    Original languageEnglish
    Article numbermdt412
    Pages (from-to)3128-3135
    Number of pages8
    JournalAnnals of Oncology
    Volume24
    Issue number12
    DOIs
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma'. Together they form a unique fingerprint.

  • Cite this

    Reid, G., Pel, M., Kirschner, M., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., McCaughan, B., Klebe, S., Brahmbhatt, H., MacDiarmid, J., & van Zandwijk, N. (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. [mdt412]. https://doi.org/10.1093/annonc/mdt412